|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 323.40 SEK | -1.76% |
|
-0.61% | +4.18% |
| 08/05 | US FDA Extends Review Period for BioArctic's Co-developed Alzheimer's Therapy | MT |
| 08/05 | Futures point to negative opening for Stockholm Stock Exchange (update) | FW |
| Capitalization | 2.92TCr 316.89Cr 268.92Cr 246.28Cr 232.21Cr 433.11Cr 30TCr 436.59Cr 1.14TCr 14TCr 1.19TCr 1.16TCr 50TCr | P/E ratio 2026 * |
499x | P/E ratio 2027 * | 32.8x |
|---|---|---|---|---|---|
| Enterprise value | 2.87TCr 311.61Cr 264.43Cr 242.17Cr 228.33Cr 425.88Cr 30TCr 429.3Cr 1.12TCr 14TCr 1.17TCr 1.14TCr 49TCr | EV / Sales 2026 * |
23.9x | EV / Sales 2027 * | 15.3x |
| Free-Float |
48.06% | Yield 2026 * |
0.61% | Yield 2027 * | 0.3% |
Last Transcript: BioArctic AB
| 1 day | -1.85% | ||
| 1 week | -0.61% | ||
| 1 month | -2.65% | ||
| 3 months | +1.19% | ||
| 6 months | +20.28% | ||
| Current year | +4.18% |
| 1 week | 313.2 |  | 337 |
| 1 month | 302.8 | | 347.4 |
| Current year | 284 | | 364.4 |
| 1 year | 169.6 | | 364.4 |
| 3 years | 137.7 | | 392 |
| 5 years | 66.7 | | 392 |
| 10 years | 20.4 | | 392 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 01/01/2013 | |
| Director of Finance/CFO | 55 | 01/06/2023 | |
| Chief Tech/Sci/R&D Officer | 65 | 01/01/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 79 | 24/01/2003 | |
| Chairman | 77 | 28/01/2003 | |
Eugen Steiner
CHM | Chairman | 72 | 01/06/2023 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.76% | -0.61% | +83.77% | +6.44% | 316.89Cr | |
| +0.09% | -2.35% | -16.86% | -16.69% | 4.33TCr | |
| -0.44% | +4.58% | +33.95% | +27.04% | 3.45TCr | |
| +1.65% | -2.54% | +256.63% | +462.65% | 3.06TCr | |
| -2.89% | +7.84% | +16.48% | -8.60% | 2.9TCr | |
| -3.58% | -3.29% | +25.92% | +23.90% | 2.73TCr | |
| +0.00% | +4.35% | - | - | 1.48TCr | |
| -6.66% | -0.11% | +183.75% | +4,189.75% | 1.35TCr | |
| -0.44% | -0.09% | +133.66% | +111.80% | 1.25TCr | |
| -0.58% | -0.89% | +3.71% | -2.97% | 1.21TCr | |
| Average | -1.45% | +1.27% | +80.11% | +532.59% | 2.21TCr | |
| Weighted average by Cap. | -1.11% | +1.44% | +67.72% | +353.33% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 120.24Cr 13Cr 11Cr 10Cr 9.56Cr 18Cr 1.24TCr 18Cr 47Cr 591.99Cr 49Cr 48Cr 2.05TCr | 180.62Cr 20Cr 17Cr 15Cr 14Cr 27Cr 1.87TCr 27Cr 70Cr 889.22Cr 74Cr 72Cr 3.08TCr |
| Net income | 5.8Cr 62.93L 53.4L 48.91L 46.11L 86.01L 60Cr 86.7L 2.26Cr 29Cr 2.36Cr 2.31Cr 99Cr | 85Cr 9.19Cr 7.8Cr 7.14Cr 6.73Cr 13Cr 875.58Cr 13Cr 33Cr 417Cr 34Cr 34Cr 1.44TCr |
| Net Debt | -49Cr -5.29Cr -4.49Cr -4.11Cr -3.87Cr -7.23Cr -503.67Cr -7.28Cr -19Cr -239.88Cr -20Cr -19Cr -830.11Cr | -151.48Cr -16Cr -14Cr -13Cr -12Cr -22Cr -1.57TCr -23Cr -59Cr -745.78Cr -62Cr -60Cr -2.58TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/26/12 | 323.80 kr | -1.64% | 48,678 |
| 11/26/11 | 329.20 kr | +3.65% | 2,23,561 |
| 08/26/08 | 317.60 kr | -4.34% | 2,82,085 |
| 07/26/07 | 332.00 kr | +0.36% | 1,53,132 |
| 06/26/06 | 330.80 kr | +1.53% | 1,25,674 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- BIOA B Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition